A detailed history of China Universal Asset Management Co., Ltd. transactions in Arvinas, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,203 shares of ARVN stock, worth $363,082. This represents 0.04% of its overall portfolio holdings.

Number of Shares
13,203
Previous 8,040 64.22%
Holding current value
$363,082
Previous $214,000 51.87%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$23.66 - $32.73 $122,156 - $168,984
5,163 Added 64.22%
13,203 $325,000
Q2 2024

Jul 19, 2024

SELL
$24.46 - $40.4 $122,887 - $202,969
-5,024 Reduced 38.46%
8,040 $214,000
Q1 2024

Apr 29, 2024

BUY
$36.38 - $52.31 $243,527 - $350,163
6,694 Added 105.09%
13,064 $539,000
Q4 2023

May 21, 2024

SELL
$14.19 - $42.33 $94,987 - $283,357
-6,694 Reduced 51.24%
6,370 $262,000
Q4 2023

Jan 23, 2024

BUY
$14.19 - $42.33 $70,893 - $211,480
4,996 Added 363.61%
6,370 $262,000
Q3 2023

May 21, 2024

BUY
$19.64 - $28.21 $13,237 - $19,013
674 Added 96.29%
1,374 $26,000
Q3 2023

Oct 30, 2023

BUY
$19.64 - $28.21 $13,237 - $19,013
674 Added 96.29%
1,374 $27,000
Q2 2023

May 21, 2024

SELL
$21.73 - $31.43 $478 - $691
-22 Reduced 3.05%
700 $17,000
Q2 2023

Jul 27, 2023

SELL
$21.73 - $31.43 $478 - $691
-22 Reduced 3.05%
700 $17,000
Q1 2023

May 21, 2024

BUY
$26.15 - $37.26 $4,733 - $6,744
181 Added 33.46%
722 $19,000
Q1 2023

Apr 27, 2023

BUY
$26.15 - $37.26 $4,733 - $6,744
181 Added 33.46%
722 $20,000
Q4 2022

May 21, 2024

SELL
$32.47 - $57.24 $406,621 - $716,816
-12,523 Reduced 95.86%
541 $18,000
Q4 2022

Jan 31, 2023

BUY
$32.47 - $57.24 $1,396 - $2,461
43 Added 8.63%
541 $19,000
Q3 2022

Oct 21, 2022

BUY
$41.87 - $57.99 $20,851 - $28,879
498 New
498 $22,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.46B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.